This week, Inventiva has received a milestone payment from Boehringer Ingelheim and extended its collaboration with AbbVie.
Today, Boehringer Ingelheim has decided today to take the next step forward and start development of the first candidate against idiopathic pulmonary fibrosis (IPF) from a research partnership with Inventiva. This has triggered a €2.5M payment for the French biotech, which is eligible to receive up to €170M if the program keeps advancing successfully.
Inventiva also had good news and an undisclosed payment from its partner AbbVie yesterday, which has decided to extend its agreement to discover oral drugs against RORγ, a promising target to treat autoimmune diseases. The aim is to find a new candidate to substitute ABBV-553, discovered through the same agreement but abandoned after Phase I.
Founded in 2011, Inventiva has managed to rapidly make its way up, sealing deals with major pharma, closing a big IPO earlier this year and developing a promising drug against non-alcoholic steatohepatitis (NASH) with the potential to outperform the competition of a new but extremely lucrative market.
Image via Optimarc / Shutterstock